Get started

Healthcare

Healthcare probably going to take a hit this weekCongress's coronavirus stimulus deal reached Friday night included a provision requiring health insurers to bear the full cost of coronavirus test kits and to waive copays. The federal government will pay the cost for the uninsured. This will probably hurt health insurers Monday, though it might be good for service providers. Here's another piece of bad news: xenophobia related to the virus has angered the Chinese government, and China’s official newspaper Xinhua published a threat to cut off supply chains for the US pharmaceutical industry. If China followed through on this threat, there could be big US drug shortages, which would be bad for pharmaceutical and healthcare companies. The whole economy will be down this week due to expanding quarantines, new travel bans, and the failure of Trump's payroll tax cut proposal, but the healthcare sector may take extra damage Monday as it bears the brunt of the cost of coronavirus testing.
AMEX:XLVShort
by ChristopherCarrollSmith
4
With meaningful stimulus coming, I'm swing trading the dipsToday Trump and Pence seemed to finally get serious about preventing a coronavirus recession, offering a payroll tax cut, a bailout of the cruise line industry, and a promise that coronavirus patients won't have to pay for testing. Admittedly these things are small potatoes compared to the scale of business disruptions that may be coming, but it was meaningful enough to reduce the PredictIt odds of recession in Trump's first term from 61% to 53%. The cruise line bailout suggests that similar bailouts may be coming for airlines, energy companies, and banks if necessary. Especially as the S&P 500 approaches its ten-year trend line, I am going to be looking at buying any large dips on the theory that additional panic selling will trigger additional panic stimulus from an administration finally waking up to the political risk of an election-year recession. I will not be playing with all of my funds, obviously. This will be risk on the order of 10-20% of my portfolio. (I already made a profit from this strategy today by buying near the mid-day low.) I wouldn't be surprised to see today's rally continue tomorrow, although the after-market movement in oil isn't promising. But even if tomorrow does turn out to be a green day, the coronavirus fear is growing as the disease spreads in the US. More downside is coming soon. I wouldn't chase today's rally; the SPX is bound to dip back toward that 10-year trend line in coming months as US economic activity continues to grind to a halt.
SP:SPX
by ChristopherCarrollSmith
SOLVE.CARE - Health Care Disruptor - Accumulate BITTREX:SOLVEBTC - Accumulate Analysis Method: Fibonacci & Wave Theory BITTREX:SOLVEBTC healthcare on the blockchain. Cut Administration waste. solve.care Motto: Making healthcare accessible, effective, and affordable Problem: In much of the developed world our population is ageing rapidly. Increased demand for care is placing an intolerable burden upon already stretched healthcare resources. Complex support infrastructures, data system silos and administrative bureaucracy have given rise to inefficiency and duplication of effort that waste billions of dollars. Incredibly, up to 30% of medical bills can go towards paying administrative costs¹. That’s simply unacceptable. Solve.Care’s revolutionary platform will significantly improve care outcomes by dramatically reducing healthcare administration costs and substantially reducing the opportunity for duplication, waste, abuse and fraud. We expect to create major cost savings by facilitating authorised peer-to-peer transactions that delegate authority to individual stakeholders while empowering payers regarding cost control and oversight.Utilizing blockchain technology, we radically reduce the unacceptable administrative burden placed on healthcare providers and enhance the care experience of individuals Learn: solve.care Will update. -AB
Long
by FibMarketWatch
Novavax (NVAX) - Vaccine Testing - SARS, MERS, SARS-CoV-2 (2019)This is an interesting idea based on outbreaks of SARS, MERS, and SARS-CoV-2 (2019). Novavax successfully created vaccines for SARS, MERS, and are on track to create one for SARS-CoV-2 (2019) - ir.novavax.com Vaccine in development for SARS-CoV-2 (2019): seekingalpha.com Is this a good investment? If the vaccination is successful and/or coronavirus outbreak continues, it could trend upwards significantly. Disclaimer: This is not financial advice. Just my own opinion based on research. Important Notes: For your own safety, the CDC recommends you WASH YOUR HANDS FREQUENTLY. COVER YOUR MOUTHS WHEN YOU COUGH/SNEEZE.
NASDAQ:NVAXLong
by traderman001
2
XLV breakout? Watch retest, quite possibly a fakeout.Healthcare is mirroring 2015-2016's triangle breakout pattern here with an obvious move above the trendline. LOTS of people see this, and there are many people viewing this as a repeat of the post 2015 rebound. I'm not totally sold on that scenario however. 2015-2016's healthcare consolidation saw a lot of frauds busted and companies deflated. Currently, we do not really have that environment to rebound from aside from the pharma companies who are going to be taking hits for opioid litigation, and we're facing some major political headwinds. While I can see some recovery from opioid settlements, I don't think we're past that as a risk quite yet, and we're coming to face other risks from the political process. With that said, I DO like healthcare. It tends to be less cyclical than other sectors, and unlike utilities & reit's, this defensive sector isn't going to kill you if we see a return to inflation / reflation at any point. Watch the breakout for a retest, and keep an eye on what it does. Markets love to fake people out, especially when everyone and their mother is seeing a repeat of previous patterns in play.
AMEX:XLV
by GTStockmaster
BEAT- BEAST is about to be unleashed...Positional/swing tradeBEAT is your prototypical aggressive growth stock- Strong future growth potential with good earning and revenue track record ... If you can overlook its debt level. This beast was tamed for a while after its share price skyrocketed from $25 to almost $80 , but it is ready to unleash its fury again. But first, I think the pullback is in the store facing key resistance lvl in confluence with ichi and BB on the weekly timeframe. In addition, short % of float is around 10%. However, it is a bullish sign when price hovers below the key resistance lvl rather than experiencing outright price rejection. My buy zone is between $45 to $55 for the positional trade. The long term trendline and S/R flip below this price range will act as a strong support. Click the like button and follow me if you like my analysis :D
NASDAQ:BEAT
by Libratus
Novartis: Buy opportunity with split entry.NVS was among the high cap losers yesterday on the renewed coronavirus tensions and pulled back dramatically (-6.90%). This however can be the buy opportunity of the next several months as it hit the 1D MA200 (orange line) and is approaching the Higher Low trend line of the 1W Channel Up (RSI = 45.378, MACD = 1.640, ADX = 65.865). Even though the MACD indicated the possibility of a deeper pull to the 84.00 1W Support before a meaningful rebound, we give equal probabilities for the rebound to start within the Higher Low zone. Our Target zone is 98.00 - 100.00. ** If you like our free content follow our profile (www.tradingview.com) to get more daily ideas. ** Comments and likes are greatly appreciated.
NYSE:NVSLong
by InvestingScope
+2068% : How the Coronavirus impact this companyHello everyone. Today I will not give a technical analysis, but I just want to show you how the coronavirus can impact the market. This company, China Health Group , has recently discover that the Ritonavir has Inhibitory effect on the new coronavirus. What is Ritonavir ? Ritonavir, sold under the trade name Norvir, is an antiretroviral medication used along with other medications to treat HIV/AIDS. This combination treatment is known as highly active antiretroviral therapy (HAART). Often a low dose is used with other protease inhibitors. It may also be used in combination with other medications for hepatitis C. Also, they are the only producer of Ritonavir in China. Ritonavir Immediately after the news was spread, this company take, in 2 days, more than 2000% . I really think that a lot of company related to the health sector, such as this one, can surge very fast. Better than a lot of shitcoin !
HKEX:8225
by GoldenNaim
1
Nasdaq Healthcare: Closing on January 17thFriday's session presented a retracement on the 20 EMA Line, as predicted. I still believe in the continuation of the bullish trend. However, the bearish divergence needs to be monitored, since further price correction could occur. Disclosure: My ideas contain statements and projections based on assumptions on capital markets, and therefore inherently subject to numerous risks and uncertainties. Before buying or selling any stock you should do your own research and reach your own conclusion or consult a financial advisor. Investing includes risks, including loss of principal. I am not a financial advisor
NASDAQ:IXHCLong
by Investing_Fellow
Nasdaq Healthcare: Closing on January 16thToday's session generated a bearish divergence on CCI. I am still bullish, but always ready for a trend retracement on the 20 EMA Line. Disclosure: My ideas contain statements and projections based on assumptions on capital markets, and therefore inherently subject to numerous risks and uncertainties. Before buying or selling any stock you should do your own research and reach your own conclusion or consult a financial advisor. Investing includes risks, including loss of principal. I am not a financial advisor
NASDAQ:IXHCLong
by Investing_Fellow
Merck: Ichimoku Clouds on bullish setupIchimoku Clouds still confirm the bullish setup. Today's session will be important, if positive, to manifest further bullish intentions (Break of the $92.10 resistance). Disclosure: My ideas contain statements and projections based on assumptions on capital markets, and therefore inherently subject to numerous risks and uncertainties. Before buying or selling any stock you should do your own research and reach your own conclusion or consult a financial advisor. Investing includes risks, including loss of principal. I am not a financial advisor.
NYSE:MRKLong
by Investing_Fellow
Nasdaq Healthcare: Closing on January 15thIf you like this idea, don't forget to support it clicking the Like Button! Positive session for Nasdaq Healthcare that gained 0.39%. However, I still see the possibility of a retracement over the basis of the Bollinger Bands indicator (orange crosses). I was waiting with anxiety today's session to check for a signal of retracement, and it comes with the third candles (17:00 - 19:00) The situation is also confirmed by RSI and CCI indicators. Disclosure: My ideas contain statements and projections based on assumptions on capital markets, and therefore inherently subject to numerous risks and uncertainties. Before buying or selling any stock you should do your own research and reach your own conclusion or consult a financial advisor. Investing includes risks, including loss of principal. I am not a financial advisor
NASDAQ:IXHCLong
by Investing_Fellow
CVS is back!After a press release indicating that CVS Health plans to open 600 new Health Hub stores this year, CVS stock has once again been climbing. I suspect the breakout will continue once CVS pushes through some resistance. I'm looking for maybe $78 per share from this run. CVS's forward P/E of about 10.5 is very attractive for a stock with large growth prospects in the next 2 years. We've got a healthcare cost bubble in the USA, and CVS may be on the leading edge of popping that bubble with its low-cost clinic model. It also boasts a roughly 2.5% dividend.
NYSE:CVSLong
by ChristopherCarrollSmith
1
Nektar is reaching fair valueNektar and Bristol-Myers Squibb announced today the companies have agreed to a new joint development plan to advance bempegaldesleukin (bempeg) plus Opdivo (nivolumab) into multiple new registrational trials (source: Yahoo Finance). The 19% jump is making Nektar trading around its fair value. Likely, profit-taking will take place in the next sessions. I'm expecting the stock price to consolidate around $23 level. Disclosure: My ideas contain statements and projections based on assumptions on capital markets, and therefore inherently subject to numerous risks and uncertainties. Before buying or selling any stock you should do your own research and reach your own conclusion or consult a financial advisor. Investing includes risks, including loss of principal. I am not a financial advisor. Don't forget to support this idea, if you liked it, and to follow me here on TradingView. Investing Fellow
NASDAQ:NKTR
by Investing_Fellow
1
Pfizer: Wide Moat and Interesting Ichimoku CloudsAfter the massive price drop at the end of July, Pfizer is pivoting its strategy selling Upjohn Unit to a new joint venture with Mylan and focusing on the new BioPharma business (mainly focusing on Ibrance, Xtandi, Inlyta, etc.). The new strategy provides Pfizer with a wide economic moat. I think the market currently undervalues the stock. The current price is above Ichimoku Green Cloud, and it coincides with the Lagging Span. I will expect a bullish progression of the price in the long term with the market correctly evaluating the new strategy. However, I see a risk of profit-taking in the next sessions anyhow, not so significant to let the stock test the upper support of the green cloud. Please, note that this analysis applies to long term positions. Don't forget to support this idea, if you liked it, and to follow me, here on TradingView. If you have another trading plan, please share in comments! Investing Fellow Disclosure: My ideas contain statements and projections based on assumptions on capital markets, and therefore inherently subject to numerous risks and uncertainties. Before buying or selling any stock you should do your own research and reach your own conclusion or consult a financial advisor. Investing includes risks, including loss of principal. I am not a financial advisor.
NYSE:PFELong
by Investing_Fellow